康拓医疗 - Financials

康拓医疗 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
+Revenue	322.0M	275.0M	240.0M	213.0M	164.0M	148.0M	110.0M	72.5M
Revenue Growth %	17.1%	14.6%	12.7%	29.9%	10.8%	34.5%	51.8%	--
Total Revenue	322.0M	275.0M	240.0M	213.0M	164.0M	148.0M	110.0M	72.5M
Cost Of Revenue	64.5M	51.8M	44.5M	36.9M	28.1M	29.8M	25.5M	22.5M
+Gross Profit	257.5M	223.2M	195.5M	176.1M	135.9M	118.2M	84.5M	49.9M
Gross Margin %	80.0%	81.2%	81.5%	82.7%	82.9%	79.8%	76.8%	68.9%
Total Operating Cost	217.0M	187.0M	161.0M	135.0M	114.0M	101.0M	86.8M	62.6M
Selling Expenses	63.7M	55.1M	47.5M	35.8M	30.7M	24.9M	21.5M	17.2M
Admin Expenses	56.0M	52.3M	44.1M	39.4M	33.9M	31.9M	28.4M	16.0M
Rd Expenses	23.9M	17.6M	18.3M	16.8M	16.9M	10.6M	8.1M	4.4M
Finance Expenses	-2.5M	-3.4M	-3.9M	-1.8M	-1.0M	-47,300	84,000	96,100
+Operating Income	106.0M	91.4M	86.3M	86.3M	51.8M	60.2M	23.4M	11.6M
Operating Margin %	32.9%	33.2%	36.0%	40.5%	31.6%	40.7%	21.3%	16.1%
Non Operating Income	537,500	469,600	2.3M	9.5M	7.0M	182,800	1.1M	141,200
Non Operating Expenses	248,000	149,700	182,100	442,200	590,900	95,600	230,000	308,100
Investment Income	-12.6M	-1.9M	3.5M	2.2M	992,400	1.2M	512,700	259,300
Asset Disposal Income	463,900	-35,400	-3,000	22,600	-22,000	-12,700	-17,600	--
Asset Impairment Loss	5.3M	8.6M	5.7M	5.0M	4.1M	1.9M	1.9M	1.3M
Other Income	13.3M	5.3M	3.6M	6.5M	858,000	12.3M	209,700	1.5M
Income Before Tax	106.0M	91.8M	88.5M	95.4M	58.2M	60.3M	24.3M	11.5M
Income Tax	18.4M	17.3M	14.3M	14.2M	7.1M	9.6M	2.9M	2.0M
+Net Income	87.6M	74.5M	74.2M	81.2M	51.1M	50.7M	21.3M	9.4M
Net Margin %	27.2%	27.1%	30.9%	38.1%	31.2%	34.3%	19.4%	13.0%
Net Income Attributable	88.4M	75.5M	75.7M	81.6M	52.4M	51.9M	22.2M	10.1M
Minority Interest	-763,100	-1.0M	-1.5M	-444,000	-1.3M	-1.2M	-809,800	-631,700
Eps Basic	1.09	0.93	0.93	1.57	1.20	1.22	0.52	0.24
Eps Diluted	1.09	0.93	0.93	1.57	1.20	1.22	0.52	0.24

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash And Equivalents	379.0M	375.0M	349.0M	325.0M	92.8M	112.0M	20.6M	40.2M
Accounts Receivable	5.9M	9.3M	10.1M	5.8M	4.1M	4.0M	5.0M	3.9M
Notes And Accounts Receivable	5.9M	9.3M	10.1M	5.8M	4.1M	4.0M	5.0M	3.9M
Prepayments	3.9M	4.9M	4.2M	3.5M	2.2M	1.5M	3.6M	2.1M
Inventory	24.8M	35.4M	38.8M	38.4M	36.4M	31.3M	23.0M	21.2M
Total Current Assets	418.0M	427.0M	404.0M	376.0M	143.0M	167.0M	81.6M	68.7M
Long Term Equity Investment	23.5M	22.3M	--	--	--	--	509,800	490,700
Fixed Assets	--	124.0M	126.0M	128.0M	28.3M	29.6M	28.2M	28.7M
Fixed Assets Total	125.0M	124.0M	126.0M	128.0M	28.3M	29.6M	28.2M	28.7M
Construction In Progress	--	10.0M	44,500	2.4M	56.3M	5.2M	--	--
Construction In Progress Total	53.9M	10.0M	44,500	2.4M	56.3M	5.2M	--	--
Intangible Assets	21.6M	21.2M	24.0M	26.2M	30.1M	23.5M	26.2M	28.0M
Long Term Deferred Expenses	3.2M	6.3M	8.6M	8.2M	54,400	222,700	728,200	1.3M
Total Non Current Assets	329.0M	249.0M	234.0M	198.0M	148.0M	61.1M	73.9M	59.9M
Total Assets	747.0M	676.0M	638.0M	573.0M	292.0M	228.0M	156.0M	129.0M
Accounts Payable	25.8M	16.8M	19.3M	15.0M	6.6M	2.7M	4.0M	5.5M
Advance Receipts	--	--	--	--	--	2.3M	1.9M	1.9M
Contract Liabilities	4.4M	1.9M	1.7M	3.2M	1.5M	--	--	--
Total Current Liabilities	94.0M	79.7M	87.6M	61.5M	37.8M	28.2M	17.0M	18.2M
Long Term Borrowings	--	--	--	--	--	--	3.8M	--
Total Non Current Liabilities	15.4M	10.6M	8.9M	10.5M	10.6M	7.7M	11.4M	8.5M
Total Liabilities	109.0M	90.3M	96.5M	72.0M	48.5M	35.8M	28.3M	26.7M
Paid In Capital	81.2M	81.2M	58.0M	58.0M	43.5M	43.5M	34.8M	34.8M
Capital Reserve	300.0M	299.0M	323.0M	324.0M	131.0M	131.0M	62.0M	59.6M
Surplus Reserve	51.7M	39.8M	28.7M	18.5M	9.7M	3.6M	7.5M	4.6M
Retained Earnings	201.0M	165.0M	132.0M	102.0M	59.4M	13.0M	21.0M	1.8M
Minority Equity	2.3M	-1.7M	-1.6M	-1.9M	-1.5M	-208,900	963,700	1.9M
Equity Attributable	636.0M	587.0M	543.0M	503.0M	245.0M	193.0M	126.0M	100.0M
Total Equity	638.0M	586.0M	542.0M	501.0M	243.0M	192.0M	127.0M	102.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020	FY 2019Dec 31, 2019	FY 2018Dec 31, 2018	FY 2017Dec 31, 2017
Cash From Sales	368.0M	310.0M	262.0M	238.0M	183.0M	166.0M	124.0M	85.3M
Tax Refunds Received	--	--	1.5M	--	647,600	--	--	--
Total Operating Cash Inflow	387.0M	328.0M	278.0M	257.0M	199.0M	181.0M	126.0M	87.6M
Cash Paid For Goods	45.3M	53.2M	34.6M	38.0M	31.0M	33.2M	28.2M	28.6M
Cash Paid To Employees	78.0M	71.3M	62.4M	45.2M	37.5M	34.2M	26.4M	14.1M
Taxes Paid	54.0M	55.0M	35.2M	26.8M	21.8M	22.0M	17.9M	11.1M
Total Operating Cash Outflow	247.0M	243.0M	186.0M	154.0M	141.0M	123.0M	103.0M	76.4M
Operating Cash Flow	140.0M	85.2M	92.0M	103.0M	57.8M	57.8M	22.8M	11.3M
Total Investing Cash Inflow	668.0M	825.0M	828.0M	437.0M	305.0M	247.0M	147.0M	110.0M
Total Investing Cash Outflow	759.0M	853.0M	857.0M	489.0M	377.0M	227.0M	179.0M	106.0M
Investing Cash Flow	-91.4M	-28.0M	-28.3M	-52.7M	-72.0M	19.9M	-31.8M	4.7M
Cash From Borrowings	--	--	15.0M	4.0M	9.2M	4.1M	3.7M	6,600
Dividends And Interest Paid	42.7M	31.8M	36.9M	30.7M	330,600	316,700	21,600	20,200
Debt Repayments	0.00	0.00	--	--	--	--	6,634	5.1M
Total Financing Cash Inflow	0.00	2.5M	15.0M	229.0M	9.2M	14.1M	3.7M	20.5M
Total Financing Cash Outflow	45.9M	34.3M	56.4M	46.1M	13.4M	316,700	14.9M	5.1M
Financing Cash Flow	-45.9M	-31.8M	-41.4M	182.0M	-4.2M	13.8M	-11.2M	15.4M
Net Change In Cash	2.6M	25.9M	23.9M	233.0M	-19.2M	91.5M	-19.6M	30.8M
Ending Cash Balance	378.0M	375.0M	349.0M	325.0M	92.8M	112.0M	20.6M	40.2M
Capex	47.4M	14.2M	18.2M	55.2M	73.0M	9.5M	4.1M	985,400